Business Summary:
A very innovative 8(a) biotech company engaged in the research of infectious diseases, whose customer base includes the federal government, commercial and academia. The company recently completed Phase I SBIR project, which could lead to the development of new diagnostics for drug resistant TB. The company has applied for a patent for gene profiling
For additional information, contact Dan Murphy at 301-572-6000 ext. 313 or by email at Dmurphy@ciworldwide.com
To learn more about Corporate Investment or to see all of our other business opportunities visit our website at www.CIWorldwide.com
|
|
|
